European Biotechnology News Special 1-2/2012 - The Lifescience Event Guide

Euro BioFairs o Compass February 2012

II The Life Sciences Events Guide

SPECIAL 31_EBSIN1-2_12_Compass_Titel_tg.indd 1

02.02.2012 12:32:52 Uhr

European Biotechnology Net work

builDing transatlantic PartnershiPs in biotechnology 30 th March | Brussels Join the European Biotechnology Network to explore how European biotechnology research can build US partnerships through the key funding mechanisms open on both sides of the Atlantic. Framework Programme Seven and Horizon 2020 from Europe combine with National Institutes of Health (NIH), Department of Defense (DOD) and the Bill and Melinda Gates Foundation from the US. Academia and industry from the US and Europe can fund partnerships through these programmes and accelerate technology and clinical/market application. The day brings together the European Commission and organisations active in EuropeanUS partnerships, from academia, SMEs and pharma, to showcase partnerships and the mechanisms behind them.

ss !

Doing the busine 2 9th March 2 012

ted by ‘Doing the busiPar tnerships is suppor Building Transatlantic istics of biotechnology log the workshop on ness’, an intensive 1 day le, the day focuses h just 15 places availab business in the US. Wit corporate par tners, ces suc with factors for beyond the technology, tion into different nts and effective integra ing, investment and gra ture. market and biotech cul click on our events iotechnology.net and Visit www.european-b k your place! to find out more and boo

In the memory of last year’s inspirational keynote speaker, Ian Bathurst, the meeting supports Medicines for Malaria Venture (MMV) a Swiss-based publicprivate initiative whose donor, stakeholder and grantee network across the US and Europe is exemplary of the kind of partnership we hope toshowcase.

Please register now at www.european-biotechnology.net through the event pages.

Meeting supported by:

Grünecker Patent- und Rechtsanwälte

European Biotechnology Foundation | Rue d’Egmont 15 | B-1000 Bruxelles, Belgique Tel: +32 2 50 08 531 | Fax +32 2 64 92 989 | info@european-biotechnology.org | www.european-biotechnology.net

EBN_EA_links_TransPartnership_210x275.indd 1

02.02.2012 12:45:28 Uhr

Nº 1-2 | Volume 11 | 2012

Euro|Biotech|News

33

Euro Biofairs Compass Intro

Half a year of superlative events © Deutsche Messe AG

Welcome to the spring conference season 2012, which offers a series of highlights that could impact your business. Whether you are looking to find a partner for drug development, to translate your products into the clinic or to look for the latest developments in laboratory and bioprocessing equipment, you’ll find all you need to know in this issue of the EuroBiotech Compass, which is now part of EuroBiotechnews – the monthly news journal for the European life sciences sector.

From bench to market – biotech events will draw hundreds of thousands of visitors in 2012.

Partnering and licence deals will be high on the agenda in March, with two events relevant to business developers in biotechnology and pharmaceutical companies – the euroPLX in Cascais (Portugal), and the BioEurope Spring in Amsterdam (The Netherlands). Both the focussed euroPLX event and the BIO-Europe’s little brother will raise the curtain on a year in which analysts say the pharmaceutical industry is expected to spend an increasing amount of money on external projects

33_EBSIN1-2_12_Special_Intro_tg.indd 33

with biotechs. Here is where Europe’s biopharmaceutical scene comes face-to-face to negotiate new license agreements.

Trade fairs & conferences Every six years, two of Europe’s major events for laboratory and biotech equipment take place in the same year. In midApril, the Munich-based Analytica opens its doors to more than 30,000 visitors, who will come to view showcased products from

more than 1,000 exhibiting companies and developers in the lab equipment sector.

Updates on technology development will be integrated into the trade fair.

Then in mid-June it will be time to head for ACHEMA – Europe’s largest conference/trade fair for biotechnology, chemical engineering and environmental protection. Around 175,000 visitors are expected to attend the event in Frankfurt, where exhibitors show off the latest progress in instrumental analytics, bioprocessing and equipment for industrial manufacture. At the associated conference, more than 900 lectures will give visitors an update on the latest research and development trends. This time around, special focusses will include biorefineries and the current research on enzymatic conversions that are relevant to the emerging idea of a bio-economy.

Another must for drug-discovery experts and users of high-throughput (HT) technologies will be taking place for the second time in Hamburg. After its successful premiere, the European Lab Automation Congress will again provide an update on progress in liquid handling, HT sequencing techniques, sample preparation and miniaturisation, along with an exhibition that includes the relevant players in the field.

In July, the Medtech Pharma 2012 congress/fair will guide researchers, developers, manufacturers and service providers through the latest developments in pharma and medical technology development. Additionally, the congress will provide insights into the latest developments in regenerative medicine, imaging, diagnostics, targeted therapies and drug delivery devices.

Beyond Europe’s borders For European companies that want to enter the Asian market, the BioTech 2012 is the place to be. The successor to BioExpo Japan is Asia’s largest drug discovery & life sciences event, and will provide the ideal opportunity to meet relevant industry figures and make business contacts. The structure of BioTech 2012 rests on three pillars: trade show, partnering and the exhibition.

B

03.02.2012 11:29:46 Uhr

34

Nº 1-2 | Volume 11 | 2012

Euro|Biotech|News

Euro Biofairs Compass

5 – 6 march, 2012 Hotel cascais miragem cascais/ Portugal

eUrO-PLX 48 LisbOn

GreetinG

Pure partnering

Efficient and valuable

Different from other matchmaking events in the pharma and biotech business, euroPLX conferences stand out because they are focused on the key to successful partnering: the face-to-face meeting. euroPLX conferences can rely on unmatched experience, with nearly 50 events since their initiation 17 years ago. A large number of pharma companies are regular guests at euroPLX meetings.

In contrast to other partnering conferences, euroPLX events focus just on business events, leaving out presentations, lectures and exhibitions. Moreover, admittance is reserved to life science executives who are in charge of their companies’ business development. euroPLX will accept service companies only provided that they “touch” the real product - at least its dossier or license. Delegates from consulting companies, associations, governments, or staff-

› QUick fActs DeLeGAtes More than 140 pharma companies in Europe are already registered.

VenUe Five-star Hotel Miragem in Cascais near Lisbon will host the event. timeLine Registration deadline is 16 February www.europlx.com

34_EBSIN1-2_12_special_PLX_pg.indd 34

ing companies are not admitted. At any partnering conference, the probability of a pre-scheduled appointment decreases with increasing size of the event, owing to the limited number of available half-hour meeting slots. For this reason euroPLX meetings deliberately limit the number of delegates admitted, but are more frequent than just once a year. The markedly different conference design results in an astonishing 23 to 25 pre-scheduled face-to-face meetings per company, a total of close to 10,000 in 2011. This makes euroPLX more productive than most, which offer just a handful of appointments. The more faceto-face meetings, the more opportunities generated. The feedback from regular euroPLX attendees indicates one signed deal for every 10 to 12 appointments, signed within anything between six weeks and three years after the initial discussions.

That’s why many companies have had delegates at more than 30 euroPLX meetings.

Customers who return repeatedly are a distinguishing mark of euroPLX. To register for euroPLX and for more information please visit www.europlx.com B

eur oP L X me etings are the ideal place for pharma deal s, attended by industry executives in charge of business development, commercial operations, marketing, and brokers or consultants with clear mandates. No other pharma or biotech partnering conference worldwide has been held as often as euroPLX, with 47 events between 1995 and 2011. Some impressions from former conference delegates: “The best value for money venue”, “most efficient and valuable”, “highly effective and pleasant”, “excellent platform”, “an indispensable tool”, “tough and intense”, “highly focussed”, “smooth organisation”, “always professional and user-friendly” – these are just some of the euroPLX attributes, as publicly stated by business development executives.

It is therefore not surprising that many companies have attended more than 30 euroPLX meetings since 1995! For us, returning customers are the best evidence of delivered benefit. See you at our three euroPLX conferences in 2012! See you in Portugal!

Dr. norbert rau RauCon Business Development Co-initiator of euroPLX

02.02.2012 12:35:11 Uhr

de in 5. Ma orld.

9 9 1 Since for the W e Europ

l) rtuga n (Po 12 Lisbo rch 5 + 6, 20

Ma

Platform for Continuity in Life Science and Pharma Business Development: Meet You @ euroPLX!

Continuity and Follow-Up

49

PLX euro

On average, euroPLX delivers 23 to 24 pre-scheduled business negotiations per company. And results.

sines us Bu inuo Cont

8 PLX 4 euro

The Leading Original

48

Partnering from innovative to generic, from early stage candidates to approved, prescription or OTC drugs.

Registrants determine the dynamically evolving focus of each euroPLX Meeting.

Displayed* and updated hourly on

Nove

) (Italy rento 2012 0 Sormber 5 + 6,

PLX 5

* as soon as sufficient data are submitted

1 50 4 euro

www.europlx.com

t men

elop s Dev

J

rkey)2 1 ul ( Tu tanb une 4 + 5, 20

Dynamic Partnering Focus

49 Is

Three times a year. Year after year. Productive continuity and shorter time to market.

Productive Partnering for Pharma Deals

euro

51

Marc

e49-50EuroBioFairs.indd 1 35_EBSIN1-2_12_Raucon.indd 1

( assolh

1 Lim

PLX 5

Kurf端rstenstr. 1A 69234 Dielheim, Germany ph. ++49 (6222) 9807-0 meetyou@europlx.com

26.01.12 11:33 01.02.2012 17:26:30 Uhr

36

Nº 1-2 | Volume 11 | 2012

Euro|Biotech|News

Euro Biofairs Compass

19 – 21 March, 2012 Amsterdam RAI Convention Center Amsterdam/The Netherlands

BIo-EuRopE SpRINg

A good year for deals BIo-Europe Spring®, the counterpart to EBD group’s flagship partnering conference BIo-Europe®, will bring bio-pharma executives and investors to Amsterdam in early 2012. At the heart of the meeting once again is partneringoNE®, a web-based system for finding development partners or investors. In addition to productive partnering, BIo-Europe Spring also offers insightful workshops and panels, company presentations and a lively exhibition.

For biotechs, 2012 is going to be a good year when it comes to finding a pharma partner. While the value of acquisitions announced by Europe’s ten largest pharma companies plunged to a1.65bn in 2011 from a33.5bn the year before, pharma patents worth a16.5bn are set to expire, according to market analyses published by Bloomberg. With growing pressure from generics, big pharma’s

interest in licensing innovative drug programmes – even in early-stage development – will grow. On 6 February, online partnering for the BIO-Europe Spring 2012 event being held on 19-21 March in Amsterdam will open.

This year, over 10,000 one-to-one meetings will be held during the three-day conference. 70 international exhibitors and more than 45 countries will showcase

gREETINg

10,000 partnering meetings, the conference is one of the most productive partnering events in the world. In addition to productive partnering, the BIO-Europe Spring also offers workshops and panels, company presentations, and a dynamic exhibition that helps you to create opportunities to power-network with your peers. I look forward to seeing you in Amsterdam!

A perfect place to find partners L i fe s cience in du s tr y dealmaker s and decisionmakers will make Amsterdam the center of partnering at the 6th annual BIO-Europe Spring®. With over

36_EBSIN1-2_12_special_BES_tg.indd 36

Carola Schropp President EBD Group, Inc.

their offerings across the life sciences value chain. In addition, more than 2,000 delegates will have the opportunity to view 120 company presentations and attend 17 workshops and panels, where industry leaders will speak about the latest trends.

In Amsterdam, the impact of new technologies on personalised oncology and the trend towards developing targeted niche busters will be high on the list of topics, along with analyses of current deals, biotech business models for faster returns and early-stage financing.

At the conclusion of BIO-Europe Spring, delegates can continue to nurture the connections made at the event with partnering360 ®. Launched last autumn at the BIO-Europe in Düsseldorf, partnering360 enables delegates to continue networking and move deals forward in-between partnering events, ensuring a highly productive and efficient partnering process. To register for BIO-Europe Spring and for more information see www.ebdgroup.com/bes B

› QuICk fACTS HIgHlIgHTS Major Partnering Event for Pharma, Biotech and Investment Executives Company Presentations, Discussion Panels, Exhibition VENuE & INfoRMATIoN Amsterdam RAI Convention Center Europaplein 22, 1078 GZ Amsterdam www.ebdgroup.com/bes

03.02.2012 11:30:44 Uhr

Join the most productive partnering platform in the life science industry

BIO-EUROPE SPRING

Producer

Supported by

®

PARTNERING FORUM

MAY 23–24, 2012 SUZHOU, CHINA

Co-producers

BIOPHARM AMERICA™

EUROMEDTECH

™

MAY 31–JUNE 1, 2012 GRENOBLE, FRANCE

CHINABIO

Producer

SEPTEMBER 19–21, 2012 BOSTON, MA, USA

Producer

Hosted by

BIO-EUROPE

BIOTECH SHOWCASE™

NOVEMBER 12–14, 2012 HAMBURG, GERMANY

JANUARY 7–9, 2013 SAN FRANCISCO, CA, USA

www.ebdgroup.com BES12 097 Kombi 210x275.indd 37_EBSIN1-2_12_EBD.indd 1 1

Co-producers

San Francisco image © San Francisco Convention & Visitors Bureau photo by K. James

MARCH 19–21, 2012 AMSTERDAM, THE NETHERLANDS

®

Partnerships start here 18.01.12 21:51 01.02.2012 17:12:18 Uhr

38

Nº 1-2 | Volume 11 | 2012

Euro|Biotech|News

Euro Biofairs Compass

17 – 20 april, 2012 neue Messe München Munich /Germany

analytica

GreetinG

Analysing success

A comprehensive overview in 5 halls Dear readers,

For more than four decades, analytica has been the international fair for state-ofthe-art laboratory technology and pioneering biotechnology. no other trade fair in the world covers lab matters in industry and science in such breadth and depth, and on such a scale. the last edition of the biennial event in 2010 attracted nearly 33,000 visitors from 120 countries, while more than 1,000 companies from 37 countries confirmed analytica’s standing as the leading trade fair for the lab tech industry. this year’s edition will try to attract even more exhibitors and visitors to springtime Bavaria.

The fair kicks off with a delightful shiver.

Germany’s best-known criminal biologist and specialist for forensic entomology, Mark Benecke, will give a presentation at the Biotech Forum on the first day demonstrating how the latest DNA analysis techniques can help catch murderers. Anyone who has drawn blood and fancies a hands-

› QUick FactS HiGHliGHtS Live Labs Mark Benecke: Forensic entomology Conference & Forums Job & Finance Day MUnicH Don’t forget to eat “Weisswurst” and drink “Weizen” beer. www.analytica.de

38_EBSIN1-2_12_special_analytica_cm.indd 38

on approach to real lab work will love the Live Labs. For the first time, Analytica will feature three completely equipped laboratories with live demonstrations daily: Forensics & Clinical Diagnostics, Plastics Analysis and Food & Water Analysis. Live Labs aside, it’s no surprise that the basic concept that has served Analytica so well over the years is remaining the same.

Three main topics are presented in five halls: Analysis & Quality Control, Biotechnology / Life Sciences / Diagnostics, and Laboratory Technology. Registered companies include a number of heavyweights such as Eppendorf, Fisher Scientific, GE Healthcare, Merck Millipore and Thermo Scientific. The industry itself is optimistic: “I assume that it will continue its growth trend of the past few years again in 2012,” says Mathis Kuchejda of the industry organization Spectaris. He may be right. In autumn 2011, German manufacturers in the sector expected sales to increase by an average of 6% in 2011 alone.

B

we look forward to welcoming you to Munich for the 23rd Analytica, the International Trade Fair for Laboratory Technology, Analysis and Biotechnology from 17–20 April, 2012. Leading manufacturers from around the world with exhibits in five halls will give visitors a compact market overview of all the latest laboratory products and equipment.

As a special highlight, for the first time ever there will be three completely equipped laboratories featuring, among other things, live demonstrations on the topics of forensics, clinical diagnostics as well as food and water analysis on each day of the fair. Thanks to the Conference and a practice-oriented supporting programme, Analytica again features an extensive range of events in 2012. And for anyone specially interested in the dynamic markets in the Asian region, we have expanded our Analytica family: With Analytica China in 2012 and Analytica Vietnam and Analytica Anacon India in 2013, you won’t miss out on any future opportunities. But first things first: Welcome in Munich!

Susanne Grödl Exhibition Director Analytica

03.02.2012 11:31:20 Uhr

AWS-BOB_Anzeige_210x275_v1.indd 1 39_EBSIN1-2_12_BOB.indd 1

07.12.11 10:51 01.02.2012 17:12:49 Uhr

40

Nº 1-2 | Volume 11 | 2012

Euro|Biotech|News

Euro Biofairs Compass

25 – 27 April, 2012 tokyo Big sight tokyo /Japan

BiO tech 2012

GreetinG

Asia’s life science hub

A unique chance to network

BiO tech, the international Biotechnology exhibition & conference, is both brand new and well-established. the event is the successor to BiO expo Japan, which has gained a reputation as the main venue for life sciences in the Asian exhibition tour. the first edition of BiO tech retains the strengths of its predecessor; it is Asia’s largest drug discovery & life science event, where experts from science and industry mingle and present cutting-edge research and new products. But along with the continuity, there have been some changes as well. For the first time, the event will be held in April, not in June. the organisers are also enhancing the international orientation and strengthening the partnering.

BIO tech is organised by one of the largest global event companies. Reed Exhibitions is responsible for 500 events in 39 countries. In 2011, Reed brought together six million participants from the Americas, Europe, the Middle East and Asia Pacific.

The subsidiary in Japan is the leading trade

› Quick FActs numBers 650+ exhibitors 28,000+ visitors 300+ sessions/seminars hiGhliGht FOrum Hundreds of researchers from business and academia mingle to exchange insights and foster relations. http://www.bio-t.jp/en/

40_EBSIN1-2_12_special_biotech2012.indd 40

event organiser in the country. With BIO tech going strong in its revamped 11th edition, the event has become the biggest life sciences meeting in the whole of Asia, and is still expanding fast. In 2012, more than 650 exhibitors are expected, a significant increase compared to last year (510).

The growth of BIO tech mirrors the astonishing development of the entire Asian life sciences sector in recent years. By establishing itself in several key niche markets, the Asian biotech and pharma industries have thrived in the global biopharmaceutical market. To cover all relevant aspects of the sector, BIO tech 2012 consists of three distinct elements: an exhibition covering biomarkers, biopharmaceuticals, bioprocessing and bioimaging as well as lab materials, a three-day conference where recent Asian bio-pharma trends are discussed, and a forum with over 200 participants from universities, institutes and the world of business. B

B I O t e c h 2 0 12 , Asia’s largest BIO event, opens it s gates in Tokyo on 25 April 2012. The conference and exhibition have been reborn from the International Bio Forum & Bio Expo Japan. With a more international and more substantial business platform, the 2012 show is expected to gather 650 exhibitors, 300 academic presenters and 28,000 visitors from all over the world.

This unique opportunity provides an ideal platform for presenting the latest developments, innovations, research and products.

With its three pillars – the exhibition, the forum with 400 sessions and the partnering with 5,000 participants – BIO tech 2012 is an event that will provide an allinclusive experience for any professional involved in drug discovery and the life sciences.

I’m sure your stay in Tokyo will give you plent y of oppor tunities to en hance your network and prepare for the market challenges that lie ahead.

Welcome to BIO tech 2012! tad ishizumi Regional President Asia North, Reed Exhibitions

03.02.2012 11:31:47 Uhr

www.permedicon.com

The International Event for Personalized Medicine Interdisciplinary Congress | Trade Exhibition | Projects

Cologne, 19 –20 June 2012

PerMediCon: the cross-sector dialogue and networking platform for the complex issue of personalized medicine.

Experts about PerMediCon: “… It was therefore high time that a dialogue-oriented platform like PerMediCon was introduced. (…) This ultimately leads to a better understanding of personalized medicine and all the possibilities it offers.”

Dr. Hagen Pfundner, CEO of Roche Pharma AG and CEO of vfa “Personalized medicine is no longer some vague vision; it has become a reality. (…)

PerMediCon can promote the sharing of expert knowledge and constructive dialogue by all relevant parties involved and is thus of primary importance for the further development of personalized medicine.”

Peer M. Schatz, CEO QIAGEN N.V. “There is no doubt that personalized medicine is coming. (…)

The only question remaining is how fast it will happen.”

Ph. D. Edward Abrahams, President Personalized Medicine Coalition Washington (USA)

Be part of the next event, which will take place from 19 to 20 June 2012 in Cologne!

For more information please visit www.permedicon.com

Supported by:

PM12_AZ_BioTechnologyNews_210x275mm_GB.indd 1 41_EBSIN1-2_12_Permedicon.indd 1

Organized by:

01.02.201226.01.12 17:13:3412:14 Uhr

42

Nº 1-2 | Volume 11 | 2012

Euro|Biotech|News

Euro Biofairs Compass

30 – 31 may, 2012 ccH congress centre Hamburg 20355 Hamburg / Germany

european Lab automation 2012

Automated success the european Laboratory automation (eLa) event aims to highlight and showcase the latest in automated instruments and workflows. Last year the mélange of informative and topical presentations attracted more than 1,500 participants.

Ken browne, director of the organising company Select biosciences, expects this number to rise to well over 2,000. but eLa is more than just a congress. it also features exhibitions and training courses focused on automated techniques, equipment and applications.

of technological innovation, and the rate of change in the field is breathtaking. The organisers are following up on last year’s event structure, combining scientific talks with exhibitions of up-to-date-technologies in socalled congress streams. Senior Director Allan M. Ferguson from Merck Healthcare, for example, will share his experiences as the keynote speaker of the “Informatics for Automation” track. The stream “Drug Discovery Automation” will be spearheaded

by Anthony Davies from Trinity College in Dublin. All in all, eight different congress streams are presented at the ELA 2012.

Among them: “Nano- and Microfluidics”, “Biobanking”, “Next-Gen Sequencing Automation” and “Liquid Handling and Robotics”.

Like the inaugural event, this year’s followup will also take place in the historic city of Hamburg. If your schedule allows you to stay a bit longer, you should consider taking part in one of the seven different training courses offered around 29 May. Registrations are accepted via the ELA-website.

B

Since 1999, Select Biosciences has gained a reputation in consulting biomedical enterprises. The organisation of conferences in this business area has also always been an important pillar. Starting last year, Select Biosciences wrapped some of its smaller congresses into one integral event: the European Laboratory Automation (ELA). And

in the same manner that lab automation saves time and multiplies capacities, ELA makes life easier and more effective for visiting industry representatives, scientists and decisionmakers. In its second year of existence, ELA has already filled the the long-felt void of a pan-European Automation event.

Lab automation is a product and a driver

GreetinG

ing over 150 scientific presentations on automation and its specific application areas within life science. With an expected attendance of over 2,000 and with more than 150 equipment vendors and supporting companies, we hope to provide life science researchers and professionals with an unparalleled opportunity to foster technological discussions and scientific collaboration. We look forward to welcoming you in Hamburg!

› QuicK FactS

Ken browne Director of Select Biosciences Event Organiser

http://selectbiosciences.com/ conferences/ELA2012

Fostering talks and collaborations Select Biosciences is delighted to announce th at Eur o p e an L ab Automation 2012 will open its gates on 30 May. 2012 will see ELA evolve into an eighttrack congress offer-

42_EBSIN1-2_12_special_ELA_ml.indd 42

numberS 150 exhibitors, 2,000 visitors 150 sessions/seminars HiGHLiGHt Forum All aspects of lab automation accessible under one roof. Combination of scientific talks, vendor exhibitions and training courses.

03.02.2012 11:32:18 Uhr

HAMBURG GERMANY 30 TO 31 MAY

2012

Welcome to our European Lab Automation congress and exhibition, Europe’s largest event dedicated to automation within life science.

Offering over 150 scientific presentations across 8 different conference streams linked with an exhibition containing more than 150 equipment vendors, ELA aims to highlight and showcase the latest in automated instruments and workflows.

Life science researchers and professionals are presented with an unparalleled opportunity to foster technological discussions and scientific collaboration.

Conference Streams •

Biobanking - Preparation, Storage and Analysis

•

Liquid Handling & Robotics

•

Drug Discovery Automation - Chemistry Automation & Compound Management

•

Nano & Microfluidics

•

Drug Discovery Automation - HCS & Cell Based Assays

•

Next-Gen Sequencing Automation

•

Informatics for Automation

•

Separation & Detection

Readers of ‘European Biotechnology News’ receive a 10% discount on their registration fee Academics please use coupon code 17263 Industry delegates please use coupon code 54344 Low cost exhibition only passes are also available

Visit www.EuroLabAutomation.com E enquiries@selectbiosciences.com P +44 (0)1787 315110 Woodview, Bull Lane, SUDBURY, CO10 0FD, UK

SelectBiosciences.com

ELA A4 European Biotechnology News ad.indd 1 43_EBSIN1-2_12_SelectBiosciences.indd 1

30/01/2012 01.02.2012 17:14:0915:31 Uhr

44

Nº 1-2 | Volume 11 | 2012

Euro|Biotech|News

Euro Biofairs Compass

18 – 22 June, 2012 Messe Frankfurt Frankfurt / Germany

AcheMA 2012

Trendsetting summit The AcheMA is the top international meeting point for decisionmakers and experts from the fields of chemical engineering, biotechnology and environmental protection. This year’s event will focus on issues relating to the energy revolution and shifts in the raw material base. For the first time, AcheMA is also launching a Partnering scheme to help an anticipated 175,000 visitors and exhibitors pinpoint suitable contacts.

ACHEMA’s portfolio is large: from laboratory and analytical techniques over pumps, compressors, valves and fittings to pharmaceutical, packaging and storage techniques and many more areas. All of these topics are of interest for the bioeconomy. In its 30th edition, the triannual event will once more be the place to be for executives in the fields of chemical engineering, biotechnology and related fields.

The fair will provide a showcase for new biotechnological processes in the manufacture of valuable compounds, as well as for smart ideas on how to integrate renewable resources into existing production cycles. The shift in the raw material base in the bioeconomy will be adressed in “BiobasedWorld at ACHEMA”. It offers the unique chance for established industry players and new market entrants – as

GreeTinG

contacts, exciting ideas… more than any of its predecessors, ACHEMA 2012 will be the global meeting point for the bio-economy. BiobasedWorld at ACHEMA, an integral part of the event, makes the bioeconomy visible throughout the exhibition and the congress – accompanied by an BIOCHEM Accelerator Forum, Technology Transfer Days, Partnering and much more.

Welcome to ACHEMA 2012!

2012 is an ACHEMA year!

Five days with more than 3,800 exhibitors and 175,000 visitors from all over the world in buzzing exhibition halls, in-depth discussion in 900 lectures, new

44_EBSIN1-2_12_special_achema_bk.indd 44

kurt Wagemann Executive Director DECHEMA e.V.

well as scientists and investors – to meet in one place and discuss state-of-the-art technologies and products. With this new concept, ACHEMA has acknowledged the fact that biotechnology and renewables now play a part in all areas of process industries. Besides scientific and technical questions, the spotlight will be on marketready concepts. With the BIOCHEM Accelerator Forum, ACHEMA offers an opportunity to network with different stakeholders in the biobased community. The Forum combines technology transfer, partnering and venture capital events in a single location. A Business Plan Competition and a series of workshops focusing particularly on business models and SMEs round off a programme that targets not only scientists and entrepreneurs, but also investors and funding organisations. Along with the exhibition, the ACHEMA’s second cornerstone is the Congress, where more than 900 lectures and up to 27,000 participants will discuss novel biocatalysts, innovative bioprocesses, biorefineries and other topics. B

› Quick FAcTs ProFile 3,800 exhibitors from 50 countries 175,000 attendees from 100 countries 30,000 executives 140,000 m² net exhibition space hiGhliGhTs BiobasedWorld at ACHEMA BIOCHEM Accelerator Forum www.achema.de

02.02.2012 12:39:07 Uhr

18 - 22 June 2012, Frankfurt am Main, Germany

| Customised GMP facilities | Customised process systems | High efficient processes | Cost-optimised production | Optimised plant availability

We look forward to seeing you.

Hall 9.1 Stand B3

www.pi.mwgroup.net M+W Process Industries GmbH A Company of the M+W Group (HQ) Lotterbergstr. 3070499 Stuttgart, Germany

45_EBSIN1-2_12_M-W.indd 1

01.02.2012 17:14:44 Uhr

46

Nº 1-2 | Volume 11 | 2012

Euro|Biotech|News

Euro Biofairs Compass

04 – 05 July, 2012 ncc ost nuremberg / Germany

Forum meDtech Pharma

GreetinG

Healthcare at heart

Networks and networking

the latest breakthroughs in medtech and Pharma will be on the agenda of medtech Pharma 2012 in nuremberg, Germany. every two years, the international congress attracts more than 1,000 researchers, developers, manufacturers, suppliers, service providers and clinical users from the medical and pharmaceutical sectors.

MedTech Pharma 2012 will again be a meeting point to make relevant contact with executives from science and companies in the med-tech and pharma sectors. For the third time since its start in 2008, the biennial congress-fair will provide insights into translational R&D in the pharmaceutical and med-tech branches.

The focus of this year’s scientific programme will be high-level lectures on intelligent biomaterials for use in re-

› Quick Facts 1,000 delegates (2010: 15 countries) 60 lectures in three sessions 100 exhibitors hiGhliGhts Symposium Medi-WING State reception at Kaiserburg castle Job market International delegations www.medtech-pharma.de

46_EBSIN1-2_12_special_medtechpharma_tg.indd 46

generative medicine, advances in molecular imaging, and applications in MIC & Endoscopy. Three of the German top clusters in medtech will present their results. Additionally, there will be a research symposium from the German Research Ministry (BMBF) with sessions under the headings BioTranspor ter, MoBi Tech, and BioDisposables.

Internationally renowned speakers at MedTech Pharma will also give an overview of the latest achievements in diagnostics, targeted therapies, new drug delivery vehicles and smart medical devices. A plenary session with top-class experts from clinics, research and industry focuses on efficiency in healthcare.

Just as in previous years, the international conference will be accompanied by a large exhibition. About 100 firms and research networks will be on hand to showcase research results, products and services. A state reception at the Kaiserburg castle on 4 July will be the highlight of the social programme. To register for MedTech Pharma and for more information visit www.medtech-pharma.de.

B

In July you are welcome to join the inter national cong r e s s M e d Te c h P h a r m a 2 012 i n Nuremberg, Germany – one of the most impor tant events for the healthcare sector in Europe. As in 2008 and 2010, we expect around 1,000 participants and more than 100 exhibitors to attend the congress. In three parallel sessions, innovations in pharma, biotech and medtech-related topics will be presented and discussed, including trends in diagnostics, pointof-care systems for near-patient testing, new approaches and molecules for targeted therapy, or new materials for regenerative medicine. In a scientific poster exhibition, the latest research results reviewed by an independent committee will be presented in the context of MedTech Pharma 2012. In addition, the congress is being used as a platform for a research symposium of the BMBF, and as an exchange network for three active leading edge clusters in the health sector. Join us at the congress!

Dr. thomas Feigl CEO Forum MedTech Pharma Senior scientific officer of Bayern Innovativ GmbH

02.02.2012 12:40:32 Uhr